Donald F. Corcoran
President and Chief Executive Officer
United States of America
Mr. Corcoran has 35 years of experience in life science companies spanning R&D operations, business development, business administration, strategy and financing. He has been involved in raising over $300 million in private and public financings and has established numerous partnerships with a value over $1.0 billion including over $160 million in upfront/guaranteed payments and support. Mr. Corcoran was a Senior Advisor to the Company and instrumental in its Series A financing. Upon the closing of this financing he was appointed President and CEO. He was most recently Chief of Staff and Head of Operations at AstraZeneca Pharmaceuticals and was part of the founding team which created Entasis Therapeutics, Inc., AstraZeneca’s antibiotic spinout. Prior to AstraZeneca he was President, CEO and a Director of MethylGene Inc., a publicly traded biopharmaceutical company. MethylGene discovered 6 novel compounds under Mr. Corcoran’s leadership which ultimately entered human clinical trials. Don has held additional leadership and management positions at Hybridon Inc., Schering Plough Pharmaceuticals and Eli Lilly and Company. He serves on the Board of Yuma Therapeutics, Inc. and has served on the Board of several biotech companies including Tranzyme, Inc. and Origenix, Inc. as well as on the SAB of the NeoMed Research Institute and Unither Virology, LLC. He received an MBA from the Johnson Graduate School of Management at Cornell University and a B.A. from Union College.